Beam Therapeutics Inc. (NASDAQ:BEAM) Relative Strength Index (RSI) is 37.83, with weekly volatility at 12.39% and ATR at 6.40. The BEAM stock’s 52-week price range has touched low of $16.80 and a $126.90 high. Intraday shares traded counted 2.29 million, which was -122.58% lower than its 30-day average trading volume of 1.03M. Its shares traded higher over the last trading session, gaining 3.24% on 05/11/21. The shares fell to a low of $56.34 before closing at $66.20. BEAM’s previous close was $64.12 while the outstanding shares total 56.62M.
Investors have identified the Biotechnology company Beam Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $4.10 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Beam Therapeutics Inc. (BEAM) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 308.32 million total, with 102.34 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -3.09 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BEAM sounds very interesting.
Is the stock of BEAM attractive?
In related news, CEO, Evans John M. sold 25,000 shares of the company’s stock in a transaction that recorded on Apr 21. The sale was performed at an average price of 70.49, for a total value of 1,762,216. As the sale deal closes, the CFO, Burrell Terry-Ann now sold 25,000 shares of the company’s stock, valued at 2,044,485. Also, President & CSO, Ciaramella Giuseppe sold 43,842 shares of the company’s stock in a deal that was recorded on Dec 30. The shares were price at an average price of 83.26 per share, with a total market value of 3,650,144. Following this completion of acquisition, the CEO, Evans John M. now holds 22,300 shares of the company’s stock, valued at 1,894,125. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.80%.
5 out of 9 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Beam Therapeutics Inc.. 0 analysts has assigned a Sell rating on the BEAM stock. The 12-month mean consensus price target for the company’s shares has been set at $104.71.